Use of high sumatriptan dosages during episodic cluster headache: Three clinical cases

Headache

Volumn 36, Issue 6, 1996, Pages 389-391

  Centonze, V ^a   Polito, B M ^a   Attolini, E ^b   Cassiano, M A ^a   Sabba C ^a   Ricchetti, G ^a   Bassi, A ^a   Cavazzuti, L ^c   Albano, O ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b Headache Centre   (Italy)

^c GSK   (Italy)

Author keywords

episodic cluster headache; side effects; sumatriptan

Indexed keywords

SUMATRIPTAN;

ADULT; ARTICLE; CASE REPORT; CLUSTER HEADACHE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYPHYLAXIS;

ADULT; CLUSTER HEADACHE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECURRENCE; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0030018080     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1996.3606389.x     Document Type: Article

References (12)

1. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991;31:291-294.
2. Connor HE, Feniuk W, Humphrey PPA. Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5-HT1-like receptor agonist. Br J Pharmacol. 1989;96:379-387.
3. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet. 1991;338:13-17.
4. Humphrey PP, Feniuk W, Motevalian M, Whalley ET. The vasoconstrictor action of sumatriptan on human isolated dura mater. In: Proceedings of the Second IUPHAR Satellite Meeting on Serotonin; July 1990; Basel, Switzerland, Basel: Birkhauser; 1991.
5. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175) selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol. 1990;99:202-206.
6. Goadsby PJ, Edvinsson L. Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine. Cephalalgia. 1991;11(suppl 11):3-4.
7. Brown EG, Endersby CA, Smith RN, Talbot JC. The safety and tolerability of sumatriptan: an overview. Eur Neurol. 1991;31:339-344.
8. Snell NJ, Russell-Smith C, Coysh HL. Myocardial ischaemia in migraine sufferers taking ergotamine. Postgrad Med J. 1978;54:37-39.
9. Centonze V, Polito BM, Di Bari M, Caporaletti P, Albano O. Vascular injuries in ergotamine abuse: a case report. Funct Neurol. 1993;8:265-270.
10. Ministero della Sanita' Direzione Generale Servizio Farmaceutico. Bollettino d'informazione sui Farmaci. 1991;1:2-4.
11. Ottervanger JP, van Witsen TB, Valkenburg HA, Grobbee DE, Stricker BH. Adverse reactions attributed to sumatriptan. A postmarketing study in general practice. Eur J Clin Pharmacol. 1994;47:305-309.
12. Buikema H, Grandjean JG. Potentiation of alpha-adrenoceptor-mediated vasoconstriction by sumatriptan. Lancet. 1993;8342:1121.